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The pregnancy-associated disease preeclampsia is related to the release of syncy-
tiotrophoblast extracellular vesicles (STBEV) by the placenta. To improve function-
al research on STBEV, reliable and specific methods are needed to quantify them. 
However, only a few quantification methods are available and accepted, though 
imperfect. For this purpose, we aimed to provide an enzyme-linked sorbent assay 
(ELSA) to quantify STBEV in fluid samples based on their microvesicle characteristics 
and placental origin.
Method of Study
Ex vivo placenta perfusion provided standards and samples for the STBEV quan-
tification. STBEV were captured by binding of extracellular phosphatidylserine to 
immobilized annexin V. The membranous human placental alkaline phosphatase on 
the STBEV surface catalyzed a colorimetric detection reaction.
Results and Conclusion
The described ELSA is a rapid and simple method to quantify STBEV in diverse liq-
uid samples, such as blood or perfusion suspension. The reliability of the ELSA was 
proven by comparison with nanoparticle tracking analysis.
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Introduction
 Extracellular vesicles (EV) play a crucial role in general cell–cell communi-
cation. Moreover, EV have been shown to be involved in the development of di-
verse diseases, such as tumor growth or preeclampsia.[1,2] Preeclampsia is one of 
the most lifethreatening disorders during pregnancy, even in the developed world. 
Preeclampsia is associated with endothelial dysfunction as well as the release of 
syncytiotrophoblast extracellular vesicles (STBEV) into the maternal circulation.
[3] The STBEV can affect immune cells, regulate coagulation, and trigger inflam-
matory processes on the endothelium.[4] A better understanding of the formation 
and function of EV would improve the understanding of related diseases. Thus, it 
is necessary to have specific methods to detect and quantify diverse EV. EV can be 
further subdivided into groups of microvesicles (100 nm to 1 µm) and exosomes 
(30–100 nm).[5] In general, microvesicles are produced by damaged or renewing 
cells, such as the syncytiotrophoblast. During the formation of microvesicles, phos-
phatidylserines are translocated to the outer side of the microvesicle membrane.
[6,7] Consequently, phosphatidylserines can be used as specific microvesicle mark-
ers. Exosomes are formed by externalization of intracellular multivesicular bodies.
[5] Due to their mode of formation, exosomes are not expected to present phos-
phatidylserines on their surface. However, a low amount of exosomes does expose 
surface phosphatidylserines.[5] Hence, it has to be taken into account that also a 
certain amount of exosomes could be comeasured when using phosphatidylserines 
as a microvesicle marker. Additionally, EV represent the molecular pattern of the 
parental cells. Therefore, STBEV are enriched with placental proteins like the en-
zyme human placental alkaline phosphatase (hPLAP), which is a broadly accepted 
specific placenta marker also on the STBEV-surface.[8] 
 There are few methods currently accepted to detect and quantify STBEV. 
The three most common methods are flow cytometry,[9] nanoparticle tracking 
analysis (NTA),[10] and enzyme-linked immunosorbent assay (ELSA).[2] Flow cy-
tometry is a common method to perform multiparametric analysis of cells and 
EV, although being limited by the particle size of the sample.[9,11] As reviewed 
by,[9] microvesicles constitute the lower size boarder for flow cytometric analysis, 
whereas exosomes cannot be analyzed due to their small size. But even the anal-
ysis of microvesicles is limited by high requirements on equipment and is more 
suitable for a characterization of the microvesicles but not for a quantification.
[9,11] NTA was proven to be a suitable way of analyzing size and quantity of diverse 
particle-enriched suspensions. NTA measures and tracks light being scattered by 
particles to follow the Brownian motion of the particles in the sample, and calcu-
lates their size and concentration based on these measured variables. The laser 
beam can also excite fluorescent dyes or quantum dots to emit light, which can 
be captured by a camera. Hence, fluorescence-labeled antibodies could be used 
to specifically label EV like STBEV and track them by NTA. However, the method
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requires the dye to have a very high intensity and half-life. This restricts the appli-
cability of fluorescence-labeled antibodies to specifically detect placenta-derived 
EV. To our knowledge, no marker of this nature is commercially available for NTA 
detection of STBEV. Additionally, the costs of purchase of the machine as well as 
antibodies have to be taken into account. The third widely accepted method to 
quantify STBEV in fluid samples is an ELSA described by the group of Redman and 
Sargent, which is based on an anti-hPLAP-antibody.[2] This antibody specifically 
binds to soluble hPLAP, and also to membranous hPLAP on the surface of the ST-
BEV. Therefore, the antibody can be applied to the ELSA for catching STBEV in fluid 
samples. As hPLAP in fluid samples, such as blood or placenta perfusates, is not ex-
pressed exclusively on STBEV, but may also appear as soluble hPLAP, the ELSA does 
not discriminate between both forms. Consequently, a strict ultra-centrifugation 
protocol has to be followed to avoid contamination by soluble hPLAP.
 Thus, research on STBEV is highly limited by the lack of specific and accept-
ed quantification methods. For this reason, the present work aimed to develop a 
specific method to quantify STBEV taking into account their microvesicle character 
as well as their placental origin. Maternal single-sided ex vivo placenta perfusion 
was performed to produce an STBEV-enriched suspension, which was pre-quan-
tified via flow cytometry. This suspension has been used for preparation of stand-
ard and reference samples for the newly developed enzyme-linked sorbent assay 
(ELSA).
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Materials and methods
Sample Acquisition and Preparation
 Samples were acquired by blood donation or ex vivo placenta perfusion 
after informed consent. Blood samples were collected in 5 mL Coagulation Mon-
ovettes (Sarstedt AG & Co., Nümbrecht, Germany). The blood was centrifuged for 
5 min at 65509 g, and plasma was collected as a supernatant. Placenta perfusion 
samples were collected by maternal single-sided or double-sided ex vivo placenta 
perfusion in a conventional perfusion cabinet (test samples) or by maternal sin-
gle-sided ex vivo placenta perfusion on a slanted plain with spikes (production of 
standard suspension for the ELSA). An intact cotyledon was chosen macroscopically 
and fixed on the perfusion device. The maternal tissue was connected to the system 
by carefully introducing four buttoned cannulae into the decidua. Prior to the main 
perfusion, the maternal side of the tissue was pre-rinsed with perfusion  suspen-
sion for 20 min in an open setup, discarding the perfused suspension containing 
maternal blood residues. During the main perfusion, the perfused suspension was 
returned to the suspension reservoir to establish a circulating setup. Perfusions 
have been performed for up to 120 or 360 min. Samples were taken at the end 
of the perfusions to be quantified with the described ELSA. The whole suspension 
of the perfusion of another placenta was collected after 300 min of perfusion, to 
gather and concentrate the included STBEV via ultra-centrifugation and to use them 
later on as quantification standards for the described ELSA (see flow cytometric 
pre-quantification of STBEV). The perfusion suspension was centrifuged for 5 min 
at 6550x g to pellet cells and large cell debris.
 Perfusion suspension was prepared as follows: 1 L NCTC-135 (with L-glu-
tamine, without phenol red, without vitamin B12, without sodium hydrogen car-
bonate; AppliChem GmbH, Darmstadt, Germany) was supplemented with 0.5 L 
Earl’s buffer, 60 g bovine serum albumin (Bovine Albumin, Fraction V, MP Biomed-
icals LLC, Solon, OH, USA), 15 g Dextran (FP 40; Serva Electrophoresis GmbH, Hei-
delberg, Germany), 2 g D-Glucose (water-free; Merck KGaA, Darmstadt, Germany), 
0.38 g Amoxicillin (Sigma-Aldrich Chemie GmbH, Hamburg, Germany), and 0.75 
mL Heparin (Heparin-Natrium-25.000, 25,000 i.E./5 mL; Ratiopharm GmbH, Ulm, 
Germany). Earl’s buffer consisted of 111.225 mM NaCl (Carl Roth GmbH + Co.KG, 





KGaA), 26.187 mM NaHCO
3









O (Merck KGaA). The pH of the perfusion suspension was adjust-
ed to pH = 7.4 with NaOH (Carl Roth GmbH + Co.KG, Karlsruhe, Germany) prior 
to filtration using a 0.8/0.2 µm filter (AcroPakTM 200 Capsules with Supor Mem-
brane; Pall Corporation, Port Washington, NY, USA) and freezing to  20°C until usage.
 Plasma and perfused perfusion suspension for STBEV standard production 
were processed via ultra-centrifugation in an Optima XL-100 ultra-centrifuge (Beck
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man Coulter GmbH, Krefeld, Germany) using ultra-centrifugation tubes (Thinwall, 
Ultra-ClearTM, 14 mL, 14 x 95 mm; Beckman Coulter GmbH) for 45 min at 100,000 
x g at 4°C. The supernatant was discarded carefully, and tubes were kept inverted 
for 30–60 s, to remove as much supernatant as possible. Pellets were resuspended 
in 500 µL (blood samples) or 6800 µL (STBEV standard) 1% (w/v) BSA in 0.05% (v/v) 
Tween 20 in PBS (Polyoxyethylene(20)-sorbitan-monolaurate, Dulbecco’s phos-
phate buffered saline; both Sigma-Aldrich Chemie GmbH). 
Flow Cytometric Pre-quantification of STBEV 
 Pre-quantification of ultra-centrifuged STBEV standard was performed by 
flow cytometry using a FACS Calibur (BD Biosciences, Heidelberg, Germany) with 
supplementation of FITC-fluorescent BD Flow CountTM Fluorospheres (BD Bio-
sciences) as a quantification marker. The placental origin of the analyzed microve-
sicles was proven by antibody-binding (mouse-anti-human placental alkaline phos-
phatase antibody, conjugated with lynx rapid RPECy5.5 antibody conjugation kit; 
both AbD Serotec, Raleigh, NC, USA). For quantification of the STBEV, the mark-
er for hPLAP-positively stained extracellular vesicles was adjusted to a sample of 
unstained STBEV as a negative control for auto-fluorescence. Based on the known 
concentration of the flow count fluorospheres, the concentration of the STBEV was 
calculated and further adjusted to 6000 STBEV/mL.
Anti-STBEV-Enzyme-linked Sorbent Assay
 Annexin V was immobilized in wells of microtiter plates (Immuno 96 Mi-
croWellTM Solid Plates, MaxiSorp, flat bottom, Nunc; Thermo Fisher Scientific 
Inc., Waltham, MA, USA) by incubation of 200 µL/well 3 µg/mL Annexin V (Sig-





, 28.5 mM NaHCO
3
, both Merck KGaA) for 20 h at 4°C. Unbound Annexin 
V was removed by washing once with 380 µL Tris-buffered saline (TBS; pH = 7.5; 
50 mM Tris-HCl; Sigma-Aldrich Chemie GmbH, 150 mM NaCl, Carl Roth GmbH + 
Co.KG). Wells were blocked with 380 µL 4% milk (powdered milk, blotting grade, 
low fat, Carl Roth GmbH + Co.KG) in TBS for 2 h at room temperature and washed 
three times with 380 µL/well 0.05% Tween 20 in TBS (Polyoxyethylene(20)-sorb-
itan-monolaurate; Sigma-Aldrich Chemie GmbH). A 100 µL sample or standard 
was applied to the respective wells and incubated for 1 h at room temperature. 
The top-standard (6000 STBEV/mL) was generated as described under ‘sample ac-
quisition and preparation’ and pre-quantified by flow cytometry as the number 
of STBEV per mL (STBEV/mL). It was applied in serial dilution of eight standard 
samples of 6000 STBEV/mL, 3000 STBEV/mL, 1500 STBEV/mL, 750 STBEV/mL, 375 
STBEV/mL, 187.6 STBEV/mL, 93.75 STBEV/mL, or a blank of 0 STBEV/mL. Wells were 
washed two times with 400 µL/well 0.05% TBS-T and afterward two times with 400 
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µL/well TBS. Samples were quantified by a colorimetric detection reaction using an 
ELSA amplification system (Invitrogen Corporation, Carlsbad, CA, USA). This system 
contains the alkaline phosphatase substrate nicotinamide adenine dinucleotide 
phosphate (NADPH), which is catalyzed by the hPLAP. For this detection reaction, 
50 µL/well substrate suspension was incubated at 25°C for 1 h and afterward 50 µL/
well amplifier suspension was added and incubated 1 h at 25°C. Color development 
was measured at 495 nm using a SPECTROstar Omega UV/Vis absorption spectrom-
eter (BMG Labtech GmbH, Ortenberg, Germany).
Nanoparticle Tracking Analysis
 Nanoparticle tracking analysis (NTA) was performed on perfusion samples, 
which were also analyzed using the ELSA described in this study. For the comparison 
of NTA and ELSA, the perfusion samples were centrifuged at 10,000 x g for 10 min 
at 4°C to remove pelleted cells and cell debris. The supernatant was further centri-
fuged at 18,900 x g for 30 min at 4°C to pellet microvesicles. The supernatant was 
discarded, and the microvesicle pellet was resuspended in 1% (w/v) BSA in 0.05% 
(v/v) Tween 20 in PBS. For optimal resolution, all samples were analyzed in 1:1000 
dilution in PBS using an LM14 NanoSight (NanoSight Malvern Instruments Compa-
ny, Malvern, Worcestershire, UK) equipped with a violet laser at 405 nm for 60 s.
Statistical Analysis
 SPSS 20 (IBM Deutschland GmbH, Ehningen, Germany) was used to per-
form statistical analysis applying the Mann–Whitney test for comparison of sample 
medians of independent samples.
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Results and discussion
 This work aimed to develop a specific method to detect and quantify STBEV 
in fluid samples based on their microvesicle character (marker: phosphatidylserine) 
and their placental origin (marker: hPLAP). For this approach, an STBEV-enriched 
suspension was produced by 5-h maternal-sided ex vivo perfusion of a human term 
placenta. The concentration of STBEV was analyzed by an established method (flow 
cytometry, Fig. 2), and suspensions of defined STBEV concentrations were pro-
duced to be used as standards for the new ELSA method (Fig. 3a). The validity of 
the described ELSA was then tested by measuring and comparing blood samples 
from healthy pregnant women and non-pregnant female blood donors (Fig. 3b). 
The microvesicle surface marker phosphatidylserine was used to capture STBEV 
by binding them to immobilized Annexin V (see functional scheme of the test in 
Fig. 1). In the detection step, the phosphatase activity of the membranous hPLAP, 
which is located on the surface of the STBEV, was utilized to perform a colorimetric 
quantification reaction. In this reaction, the alkaline phosphatase substrate (NA-
DPH) is cleaved by hPLAP which initiates a cyclic enzyme reaction resulting in the 
formation of the detectable Formazan molecule. Single-sided ex vivo placenta per-
fusion provided an enriched STBEV standard suspension, which was pre-quantified 
via flow cytometry (Fig. 2). For this pre-quantification, the placenta-derived STBEV 
were stained with an hPLAP specific antibody and mixed with commercially avail-
able quantification beads of known concentration. Both the quantification beads 
and the hPLAP-positive STBEV were tracked by flow cytometry. Comparison of the 
amount of both fractions (Fig. 2) allowed the recalculation of the STBEV concen-
tration, which was further adjusted to 6000 STBEV/mL. This top-standard served 
as the starting concentration of the standard samples in all of our tests. It was se-
rially diluted to give standard samples of 6000 STBEV/mL, 3000 STBEV/mL, 1500 
STBEV/mL, 750 STBEV/mL, 375 STBEV/mL, 187.6 STBEV/mL, 93.75 STBEV/mL, or a 
blank of 0 STBEV/mL. In general, common flow cytometry still suffers from accuracy 
and sensitivity problems in regard to microvesicle quantification.[9,11] Because of 
this, the STBEV concentration achieved by flow cytometry has to be regarded as 
relative numbers only, still being sufficient to give a relative STBEV concentration 
for this standard.
 These standard samples were used to plot a curve showing the typi-
cal distribution of standards applied to ELSA or comparable analysis (Fig. 3a). 
The standard curve started with a nearly linear slope in the range of the low-
er concentrations, then increased to a plateau at the higher concentrations. 
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Fig. 1 Functional principle of the anti-STBEV-ELSA. 
In the described enzyme-linked sorbent assay (ELSA), Annexin V is immobilized on the surface of microtiter plates. 
It works as a capturing molecule by binding phosphatidylserine on the surface of the syncytiotrophoblast extracel-
lular vesicles (STBEV). The membranous human placental alkaline phosphatase (hPLAP) on the STBEV catalyzes a 
colorimetric detection reaction.
Fig. 2 Flow cytometric pre-quantification of a STBEV sample. 
Four STBEV samples were independently isolated from the perfusion suspension of one maternal single-sided ex 
vivo placenta perfusion. STBEV were stained with Cy5.5 labeled anti-hPLAP antibodies. The histograms show the 
staining intensity (x-axis) and particle count (y-axis) of hPLAP-positive vesicles (a; overlay of four separate analyses, 
left curve shows unstained STBEV) and of FITC-fluorescent flow count beads (b; overlay of four separate analyses), 
which were used for calculation of the STBEV concentration. Based on these results, the STBEV concentration was 
adjusted for its application as the top-standard of the standard row for the described ELSA.
Fig. 3 Exemplary measurements with the STBEV-ELSA. 
(a) Measurement of the standard series, which was isolated from the perfusion suspension of a maternal sin-
gle-sided ex vivo placenta perfusion. (b) STBEV quantification in control blood of a non-pregnant woman  (negative 
control) and six pregnant women at term. The bars show mean values of duplicates for the samples of pregnant 
women at term. The non-pregnant control was measured 12 times in total (measurement of duplicates on six dif-
ferent plates). Error bars indicate the standard error of the mean. *P < 0.05 (Mann–Whitney test).
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 Test measurements were performed with the plasma of six pregnant do-
nors and a non-pregnant donor as negative control (Fig. 3b). All pregnant women 
could be distinguished significantly (P < 0.05) from the negative control. The sub-
strate for the detection reaction is a potential target for different types of alkaline 
phosphatases. Furthermore, plasma samples include microvesicles from multiple 
cell types [7] that are also phosphatidylserine positive and will compete with STBEV 
for binding to the Annexin V. However, only the samples from pregnant women 
featured a positive signal which underlines the specificity of the test. Even samples 
from ex vivo placenta perfusion (Fig. 4) were successfully analyzed with the de-
scribed method. As expected, samples from ex vivo placenta perfusion turned out 
to be highly concentrated, so dilution of these samples prior to the measurement is 
highly recommended in this assay.
 To confirm the reliability of this ELSA, results acquired by ELSA were com-
pared to those acquired by NTA analysis of the same samples. The results obtained 
by the anti-STBEV-ELSA could be verified by NTA (Fig. 4). The differences observed 
in the results of these methods may be due to the differences in the test systems. It 
is known that a very high proportion of microvesicles in blood originates from plate-
lets and endothelial cells.[7] Thus, it also can be expected that placenta perfusates 
are not only enriched with placental extracellular vesicles, but also with extracel-
lular vesicles derived from endothelial or other cells residing in the placenta (e.g., 
decidual cells) or residual circulatory cells (e.g., blood cells). In contrast to the NTA, 
the ELSA is more specific and measures only the placental vesicle fractions. This 
explains the discrepancies in the results of the two tests.
 The test described here is comparable to a conventional ELSA, but works 
without the immune-active component. Therefore, our assay represents an en-
zyme-enhanced sorbent assay (ELSA). The exclusion of the immune-active compo-
nent can reduce the susceptibility for disturbances of the test because it reduces 
the working steps in the assay.
 There are some limitations to this method. One may argue that also oth-
er EVs, but not exclusively STBEVs, may have an phosphatase activity. As shown 
in Fig. 3, in non-pregnant plasma, the detected EV concentration is comparatively 
low, which indicates low activity of EVs other than STBEVs. The standard suspension 
which was applied here was produced by perfusion of only one placenta, but the 
distribution of hPLAP and PS on the surface of STBEV might vary between sam-
ples from diverse patients. Thus, it may be advisable to collect perfusion material 
of more placentae and to mix the suspensions to produce a more representative 
standard suspension. For this reason, the ascertained values should be regarded 
only as relative values and not as total vesicle counts. Also the pre-quantification 
of the standard via flow cytometry gives only relative STBEV quantities due to ac-
curacy and sensitivity problems of the method regarding microvesicle analysis.[11] 
Furthermore, it is advisable to prepare the standard and samples, which shall be 
analyzed, following the same preparation protocol. If both specimens are isolat
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ed with the same centrifugation speeds, the quantification of the samples based 
on the standard will be even more reliable. Nevertheless, the test presented here 
revealed its usefulness for the purpose of quantifying STBEV, especially in lower ST-
BEV concentration ranges. This test will also be very beneficial in functional STBEV 
analysis by providing a rapid, simple, and cost-efficient quantification method. The 
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Fig. 4 Comparison of the STBEV quantification achieved via ELSA and the total microvesicle quantification 
achieved via NTA. 
Samples from ex vivo placenta perfusion were analyzed with ELSA and NTA. As the ELSA is based on measurement 
of the placenta-specific hPLAP activity on captured extracellular vesicles, it provides STBEV concentrations (x-axis). 
In contrast, the NTA (y-axis) measures all microvesicles, not only the ones derived from syncytiotrophoblast. The 
linear fit line of the comparison of the ELSA and the NTA values and the 95% confidence interval are  indicated by 
the line and the two ambient curves.
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